Search published articles


Showing 4 results for Irritable Bowel Syndrome
The effect of bismuth subcitrate in patients with diarrhea predominant irritable bowel syndrome
Kalani M, Foroutan H, Rahimi R, Ghofrani H, Ahadpoor Behnami Sh,
Volume 68, Issue 6 (9-2010)
Abstract

Background: The irritable bowel syndrome (IBS) is one of the most common chronic medical conditions. Various mechanisms, including altered gut flora and/or small bowel bacterial overgrowth, have been suggested to play a role in the development of gas-related symptoms aim of study. The clinical evidence of small intestinal bacterial overgrowth as an important etiology of irritable bowel syndrome continues to accumulate. Clinical symptoms of bacterial overgrowth and irritable bowel syndrome are similar however, a definitive cause-and-effect relationship remains unproven. It is unclear whether motility dysfunction causes bacterial overgrowth or gas products of
enteric bacteria affect intestinal motility in irritable bowel syndrome.

Methods: In a randomized double-blind placebo-controlled trial consisting of treatment with bismuth subcitrate. Primary efficacy variable was subjective symptoms frequency of abdominal pain, Number of bowel movement & Bloating/distension.

Results: 119 patients were enrolled (59 bismuth subcitrate and 60 placebo recipients). At the end of phase 2, all symptom scores dropped significantly both in bismuth subcitrate and placebo group (p<0.001). There was not a significant difference in symptom relief with bismuth subcitrate versus placebo administration.

Conclusions: There was not a significant difference in symptom relief with bismuth subcitrate versus placebo in IBS patients. Whether antibiotics can improve quality of life in patients with irritable bowel syndrome warrants further research.
Interventions: Participants were randomly assigned to receive 120mg bismuth subcitrate four times daily for 14 days (n=59) or placebo (n=60).


Doxepin is more effective than nortriptyline and placebo for the treatment of diarrhea-predominant irritable bowel syndrome: a randomized triple-blind placebo-controlled trial
Ghadir Mr, Habibinejad H, Heidari A, Vahedi H,
Volume 69, Issue 6 (9-2011)
Abstract

Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 Background: The current treatment of IBS is often unsatisfactory and frustrating. Several controlled trials have demonstrated benefits of tricyclic antidepressants for irritable bowel syndrome, especially when pain is a prominent symptom but the efficacy of antidepressants in irritable bowel syndrome is controversial. The aim of this study was to compare the effect of doxepin and nortriptyline on diarrhea-predominant irritable bowel syndrome.
Methods: Seventy-five patients with IBS according to Rome III criteria were treated for two months. The patients were randomly assigned to one of three groups treated with doxepin, nortriptyline or placebo. Subjects were assessed clinically one month and two months after treatment. The symptoms and adverse effects of the drugs were recorded in the questionnaire. The total score was considered as the number of the symptoms for each patient, which ranged between zero and six.
Results: Improvements in abdominal pain and bloating in the doxepin group were significantly higher than the nortriptyline or the placebo groups (P=0.001 and P=0.012, respectively). However, improvement in diarrhea in patients on nortriptyline was significantly higher than the other groups (P=0.018). The average improvement of symptoms in the patients after two months of treatment in doxepin, nortriptyline and placebo groups, respectively were 2.56, 2 and 0.6 (P<0.05).
Conclusion: Both doxepin and nortriptyline are effective for the treatment of diarrhea-predominant irritable bowel syndrome in a period of two months but doxepin seems to be more efficacious than nortriptyline in this regard. However, larger comparative trials are suggested.


The effect of curcumin capsule on quality of life and symptoms of patients with irritable bowel syndrome: a double blind clinical trial
Negar Sahba, Alireza Amani, Mohammadreza Rohani, Rahmatallah Moradzadeh , Azim Forouzan, Mojtaba Ahmadlou,
Volume 81, Issue 1 (4-2023)
Abstract
Background: Improving the quality of life of patients is the main goal of therapeutic interventions in chronic diseases. One way to achieve this is to decrease the severity of symptoms. The aim of this study was to investigate the effect of curcumin capsule on quality of life and symptoms of patients with irritable bowel.
Methods: This clinical trial study was performed on 60 patients with irritable bowel syndrome referred to Amir al-Momenin Hospital in Arak city from April to September 2018, using convenience sampling and Extra-intestinal symptoms severity scale and WHOQOL_BREF tools. The patients were divided into two groups of intervention and control, curcumin capsules were used in the first one, and in the second one, placebo capsules were used twice a day after lunch and dinner for four weeks. All patients were examined at the beginning of the study, the fourth week and three months later, in terms of quality of life, severity and frequency of symptoms and possible complications. During this period, the patients were followed up on a monthly basis through phone calls, and the contact number of the researcher was provided to the patients to call in case of any problems or questions.
Results: The average age of the curcumin group was 35 years and for the placebo group was 36.43 years. There was no significant difference in the quality of life between the curcumin and placebo groups after the intervention (P>0.05). Significant were found between the curcumin and placebo groups after the intervention (P<0.05).
Conclusion: The results of this study showed that there was a significant difference between curcumin and placebo in improving the clinical symptoms of patients, but the quality of life of patients in both curcumin and placebo groups did not change significantly after the intervention.

Comparison of the effect of sequential use of metronidazole and probiotics with probiotics alone on functional bloating
Maryam Soheilipour, Aliakbar Gorjipour , Mojtaba Mohammadpour, Elham Tabesh, Mohammad Javad Tarrahi ,
Volume 81, Issue 8 (11-2023)
Abstract
Background: Most people often complain of abdominal bloating. The present study was designed and conducted with the purpose of examining the effect of sequential treatment of Metronidazole and Probiotics, and Probiotics alone in reducing the severity of symptoms of functional bloating.
Methods: The present study was a randomized clinical trial that was carried out from March 2022 until June 2023 in Isfahan and Khurshid Hospital. The studied population were suffering from flatulence and were diagnosed with functional bloating by a gastroenterologist based on Rome III criteria. Then they entered one of the two study groups in a double-blind manner. The first group was treated with Metronidazole for two weeks and then with Probiotic for two weeks. The second group was treated with Probiotic for four weeks. The severity of patients' bloating was measured by a 4-question questionnaire in five stages: before the start of the study, two weeks after, four weeks after, six weeks after, eight weeks after and 12 weeks after the start of the study.  Finally, the obtained information was entered into SPSS software version 24 Repeated measures ANOVA was used to investigate the relationship between variables.
Results: After collecting the data, 43 patients in the first group and 44 patients in the second group were examined. 72.1% of the first group were women and 27.9% were men. In group two, this ratio was 72.7% for women and 27.3% for men. In this intervention, it was seen that in the 1st group, the average severity of bloating decreased until the end of the eighth week and after the second week of drug treatment, and then increased. In the second group, the average intensity of bloating decreased until the end of the fourth week and at the same time as the end of drug treatment, and then increased.
Conclusion: It was shown that in the study, the effect of this combined treatment had a greater effect in reducing the severity of functional bloating among patients with functional bloating.

Page 1 from 1     

© 2024 , Tehran University of Medical Sciences, CC BY-NC 4.0

Designed & Developed by : Yektaweb